|
APN
APN
APN - Aspen Pharmacare Holdings - 2010 Anti-Retroviral Tender Results
ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
Registration number 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
("Aspen" or "the Company")
2010 ANTI-RETROVIRAL TENDER RESULTS
Following the announcement of the Anti-Retroviral (ARV) Tender results by the
South African National Treasury Department, Aspen Pharmacare Holdings Limited is
pleased to announce that its South African operating company (Aspen) has been
successful in winning a number of key products in the tender, including
Efavirenz and Tenofovir, in spite of strong competition. The tender is effective
for a period of two years, commencing 01 January 2011.
Aspen secured approximately 40% of the awarded tender value based upon expected
future demand as published in the invitation to tender. The tender value is
estimated to be R3.6 billion over 2 years. The South African ARV Tender is the
largest of its kind in the world. Aspen has been a leading supplier to this
tender since inception of the programme, providing a consistent and reliable
supply of high-quality ARV products to the State.
Aspen was awarded a share of the following products:
Product % Awarded to Aspen
Abacavir Solution 20mg/ml 40%
Efavirenz Tablets 600mg 70%
Lamivudine Scored Tablets 150mg 70%
Nevirapine Tablets 200mg 40%
Tenofovir Tablets 300g 70%
Zidovudine Tablets 300mg 40%
These tender results are further testament to Aspen`s cost competitiveness
against both local and foreign suppliers. Aspen`s range of ARV`s are produced at
its world-class manufacturing facilities in Port Elizabeth, South Africa. The
Group has invested more than R2 billion over the last five years in extending
its manufacturing capability and enhancing the existing facilities. This has
resulted in unlocking capacity to accommodate growing demand from Aspen`s
domestic and foreign territories and also contributed towards further optimising
manufacturing efficiencies.
In his response to the ARV Tender results, Aspen Group Chief Executive, Stephen
Saad said: "These tender results confirm Aspen`s cost competitiveness and its
credibility as a reliable supplier of pharmaceutical products. Aspen is proud to
be able to contribute towards increasing access to affordable, high quality
medicines in South Africa and thereby assist in the treatment of the HIV/AIDS
pandemic."
Aspen`s portfolio of ARV`s supports close to 900 000 patients in South Africa
daily.
14 December 2010
Sponsor:
Investec Bank Limited
Date: 14/12/2010 10:24:01 Produced by the JSE SENS Department.
The SENS service is an information dissemination service administered by the
JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or
implicitly, represent, warrant or in any way guarantee the truth, accuracy or
completeness of the information published on SENS. The JSE, their officers,
employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature,
howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
| Profile Group (Pty) Ltd. has taken care in preparing all information on this website, but does not accept any liability for errors or out-of-date information. | |||||||||||||
| Other Profile Group sites: FundsData Online (unit trust data) | Profile Group corporate site | |||||||||||||
| [ Terms of Use | Privacy Policy | PAIA manual | FAQs/Help | Site Map | © Copyright Reserved 2026 ] | |||||||||||||
|
|||||||||||||
